Trials and Noteworthy Treatments

			Treatment Next 25		Location		Last Updated
	Details		NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303		Kingston, Ontario, CANADA Edmonton, Alberta, CANADA Moncton, New Brunswick, CANADA Ottawa, Ontario, CANADA Toronto, Ontario, CANADA Winnipeg, Manitoba, CANADA Phoenix, AZ La Jolla, CA Palo Alto, CA Sacramento, CA Aurora, CO Englewood, CO Jacksonville, FL Orlando, FL Chicago, IL Evanston, IL Boston, MA Detroit, MI Winston-Salem, NC Edison, NJ Buffalo, NY Columbus, OH Columbus, OH Portland, OR Memphis, TN Nashville, TN Seattle, WA Madison, WI		03/01/2008

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 6 of 6
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

•   (0.9972)   Neurobiological Technologies` Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
  
  
•   (0.9688)   Celtic Pharma - Update on XERECEPT
  
  
•   (0.9115)   Celtic Pharma and Neurobiological Technologies Present an Update on XERECEPT(R) for Peritumoral Brain Edema at the 11th Annual Meeting of the Society For Neuro-Oncology
  
  
•   (0.9115)   Neurobiological Technologies, Inc. Announces Holding of Investigators Meeting For Phase III Trials for XERECEPT(TM)
  
  
•   (0.8912)   XERECEPT UPDATE
  
  
•   (0.8169)   Emeryville drug maker sells brain tumor drug for $33 million
  
  

Frequently Asked Questions